Abstract
Thyroid cancer (TC) is the most prevalent malignancy of the endocrine system, and its incidence has been increasing worldwide in recent years. Although it generally has a favorable prognosis, aggressive forms, such as anaplastic TC, are associated with high mortality rates. Cell-microenvironment interactions largely influence the progression and metastatic behavior of TC however, the precise mechanisms underlying these processes remain inadequately understood. One critical factor influencing metastasis is anoikis, a form of programmed cell death triggered by the detachment of cells from the extracellular matrix. Resistance to anoikis allows tumor cells to escape apoptosis, survive in circulation, and metastasize to distant organs. Given this pivotal role in metastasis, anoikis resistance represents a key area of study in understanding cancer progression. This review will discuss the molecular mechanisms and pathogenesis of TC, with a focus on the role of anoikis resistance in metastatic spread and thus its potential as a therapeutic target.
Keywords: Thyroid cancer, anoikis, metastasis, apoptosis, extracellular matrix
Read the full text
1 section · 3 figures · 1 table · PDF
Create your free account to read the full text.
- Full text with figures and tables
- PDF and supplementary files
- Access on every Galenos journal
One Galenos account works on every Galenos journal site.
References
Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet. 2023;401:1531-1544. Epub 2023 Apr 3
Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities. Biochim Biophys Acta Rev Cancer. 2023;1878:188928.
Cherella CE, Wassner AJ. Pediatric thyroid cancer: Recent developments. Best Pract Res Clin Endocrinol Metab. 2023;37:101715. Epub 2022 Nov 7
Paulson VA, Rudzinski ER, Hawkins DS. Thyroid cancer in the pediatric population. Genes (Basel). 2019;10:723.
Bauer AJ. Molecular genetics of thyroid cancer in children and adolescents. Endocrinol Metab Clin North Am. 2017;46:389-403. Epub 2017 Feb 23
Hoda SA, D’Alfonso TM. Sternberg’s Diagnostic Surgical Pathology. 6th ed. Wolters Kluwer Health; 2015. p. 533-594.
Zhu J, Wang Y, Chen L, Liu P, Li R, Qiao J. Growth hormone supplementation may not improve live birth rate in poor responders. Front Endocrinol (Lausanne). 2020;11:1.
Puga FM, Correia L, Vieira I, Caetano JS, Cardoso R, Dinis I, Mirante A. Differentiated thyroid cancer in children and adolescents: 12-year experience in a single center. J Clin Res Pediatr Endocrinol. 2024;16:314-322. Epub 2024 Apr 29
Cetin SK, Siklar Z, Ozsu E, Ceran A, Ceyhan K, Aycan Z, Kırmızı A, Dincaslan H, Unal E, Berberoğlu M. Familial clinical heterogeneity of medullary thyroid cancer with germline RET S891A protooncogene mutation: 7-year follow-up with successful sorafenib treatment. J Clin Res Pediatr Endocrinol. 2023;17:345-351.
Saharat K, Lirdprapamongkol K, Chokchaichamnankit D, Srisomsap C, Svasti J, Paricharttanakul NM. Tumor susceptibility gene 101 mediates anoikis resistance of metastatic thyroid cancer cells. Cancer Genomics Proteomics. 2018;15:473-483.
Zhao W, Chen S, Hou X, Chen G, Zhao Y. CHK2 promotes anoikis and is associated with the progression of papillary thyroid cancer. Cell Physiol Biochem. 2018;45:1590-1602. Epub 2018 Feb 26.
Lee JJ, Hsu YC, Li YS, Cheng SP. Galectin-3 inhibitors suppress anoikis resistance and invasive capacity in thyroid cancer cells. Int J Endocrinol. 2021;2021:5583491.
Tang M, Luo W, Zhou Y, Zhang Z, Jiang Z. Anoikis-related gene CDKN2A predicts prognosis and immune response and mediates proliferation and migration in thyroid carcinoma. Transl Oncol. 2024;40:101873.
Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184-199.
Fugazzola L, Muzza M, Pogliaghi G, Vitale M. Intratumoral genetic heterogeneity in papillary thyroid cancer: Occurrence and clinical significance. Cancers (Basel). 2020;12:383.
Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569-580.
Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist. 2013;18:926-932. Epub 2013 Jul 19
Nikita ME, Jiang W, Cheng SM, Hantash FM, McPhaul MJ, Newbury RO, Phillips SA, Reitz RE, Waldman FM, Newfield RS. Mutational analysis in pediatric thyroid cancer and correlations with age, ethnicity, and clinical presentation. Thyroid. 2016;26:227-234. Epub 2016 Jan 7
Mitsutake N, Saenko V. Molecular pathogenesis of pediatric thyroid carcinoma. J Radiat Res. 2021;62(Suppl 1):i71-i77.
Placzkowski KA, Reddi HV, Grebe SK, Eberhardt NL, McIver B. The role of the PAX8/PPARgamma fusion oncogene in thyroid cancer. PPAR Res. 2008;2008:672829. Epub 2008 Oct 29
Fagin JA, Krishnamoorthy GP, Landa I. Pathogenesis of cancers derived from thyroid follicular cells. Nat Rev Cancer. 2023;23:631-650. Epub 2023 Jul 12
Hsiao SJ, Nikiforov YE. Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer. 2014;21:T301-T313. Epub 2014 May 14
Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013;1833:3481-3498. Epub 2013 Jul 2
Çumralı Yılmaz S, Savlav G, Altun Z. Anoikis. In: Cell Death: Mechanisms and Experimental Research Models in Disease and Health. Manisa: Manisa Celal Bayar University; 2022. p. 22-32.
Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124:619-626. Epub 1994 Feb 1.
Gilmore AP. Anoikis. Cell Death Differ. 2005;12 Suppl 2:1473-1477.
Taddei ML, Giannoni E, Fiaschi T, Chiarugi P. Anoikis: An emerging hallmark in health and diseases. J Pathol. 2012;226:380-393.
Thornberry NA. Caspases: Key mediators of apoptosis. Chem Biol. 1998;5:R97-R103.
Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, Newmeyer DD. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17:525-535.
Taylor RC, Cullen SP, Martin SJ. Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9:231-241.
Valentijn AJ, Gilmore AP. Translocation of full-length Bid to mitochondria during anoikis. J Biol Chem. 2004;279:32848-32857.
Rosen K, Shi W, Calabretta B, Filmus J. Cell detachment triggers p38 mitogen-activated protein kinase-dependent overexpression of Fas ligand. A novel mechanism of anoikis of intestinal epithelial cells. J Biol Chem. 2002;277:46123-46130. Epub 2002 Sep 27.
Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem. 1998;273:2926-2930.
Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol. 1997;9:701-706.
Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, Defilippi P. Integrins induce activation of EGF receptor: Role in MAP kinase induction and adhesion-dependent cell survival. EMBO J. 1998;17:6622-6632.
Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors. Curr Opin Cell Biol. 2005;17:559-564.
Orford K, Orford CC, Byers SW. Exogenous expression of beta-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J Cell Biol. 1999;146:855-868.
Haller H, Kunzendorf U, Sacherer K, Lindschau C, Walz G, Distler A, Luft FC. T cell adhesion to P-selectin induces tyrosine phosphorylation of pp125 focal adhesion kinase and other substrates. J Immunol. 1997;158:1061-1067.
Brenner B, Gulbins E, Schlottmann K, Koppenhoefer U, Busch GL, Walzog B, Steinhausen M, Coggeshall KM, Linderkamp O, Lang F. L-selectin activates the Ras pathway via the tyrosine kinase p56lck. Proc Natl Acad Sci U S A. 1996;93:15376-15381.
Buchheit CL, Rayavarapu RR, Schafer ZT. The regulation of cancer cell death and metabolism by extracellular matrix attachment. Semin Cell Dev Biol. 2012;23:402-411.
Adeshakin FO, Adeshakin AO, Afolabi LO, Yan D, Zhang G, Wan X. Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming. Front Oncol. 2021;11:626577.
Ayla S, Karahüseyinoglu S. Cancer stem cells, their microenvironment and anoikis. Crit Rev Oncog. 2019;24:27-34.
Wu Y, Zhou BP. Snail: More than EMT. Cell Adh Migr. 2010;4:199-203. Epub 2010 Apr 14
Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12:9-22.
Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455-7464.
Avizienyte E, Frame MC. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol. 2005;17:542-547.
Giannoni E, Buricchi F, Grimaldi G, Parri M, Cialdai F, Taddei ML, Raugei G, Ramponi G, Chiarugi P. Redox regulation of anoikis: Reactive oxygen species as essential mediators of cell survival. Cell Death Differ. 2008;15:867-878. Epub 2008 Feb 8
Langley RR, Fidler IJ. The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011;128:2527-2535. Epub 2011 Mar 25
Lin JD. The role of apoptosis in autoimmune thyroid disorders and thyroid cancer. BMJ. 2001;322:1525-1527.
Lin HY, Chin YT, Yang YC, Lai HY, Wang-Peng J, Liu LF, Tang HY, Davis PJ. Thyroid hormone, cancer, and apoptosis. Compr Physiol. 2016;6:1221-1237.
Holm TM, Yeo S, Turner KM, Guan JL. Targeting autophagy in thyroid cancer: EMT, apoptosis, and cancer stem cells. Front Cell Dev Biol. 2022;10:821855.
Manzella L, Stella S, Pennisi MS, Tirrò E, Massimino M, Romano C, Puma A, Tavarelli M, Vigneri P. New insights in thyroid cancer and p53 family proteins. Int J Mol Sci. 2017;18:1325.
Jensen K, Patel A, Klubo-Gwiezdzinska J, Bauer A, Vasko V. Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis. Endocr Relat Cancer. 2011;18:613-626.
Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M, Ringel MD. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A. 2007;104:2803-2808. Epub 2007 Feb 12
Huber MA, Kraut N, Beug H. Molecular requirements for epithelialmesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548-558.
Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet. 2004;41:161-170.
Leng C, Zhang ZG, Chen WX, Luo HP, Song J, Dong W, Zhu XR, Chen XP, Liang HF, Zhang BX. An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway. Cancer Lett. 2016;376:188-196. Epub 2016 Mar 17
Friedland JC, Lakins JN, Kazanietz MG, Chernoff J, Boettiger D, Weaver VM. Alpha6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-kappaB-dependent resistance to apoptosis in 3D mammary acini. J Cell Sci. 2007;120:3700-3712. Epub 2007 Oct 2
Pan Y, Zhu X, Wang K, Chen Y. MicroRNA-363-3p suppresses anoikis resistance in human papillary thyroid carcinoma via targeting integrin alpha 6. Acta Biochim Biophys Sin (Shanghai). 2019;51:807-813.
Lima CR, Gomes CC, Santos MF. Role of microRNAs in endocrine cancer metastasis. Mol Cell Endocrinol. 2017;456:62-75. Epub 2017 Mar 18
Wang T, Xu H, Qi M, Yan S, Tian X. MiRNA dysregulation and the risk of metastasis and invasion in papillary thyroid cancer: A systematic review and meta-analysis. Oncotarget. 2018;9:5473-5479.
Zhao R, Lu Y, Wan Z, Qiao P, Yang L, Zhang Y, Huang S, Chen X. Identification and validation of an anoikis-related genes signature for prognostic implication in papillary thyroid cancer. Aging (Albany NY). 2024;16:7405-7425. Epub 2024 Apr 24
Shao Z, Ji W, Liu A, Qin A, Shen L, Li G, Zhou Y, Hu X, Yu E, Jin G. TSG101 silencing suppresses hepatocellular carcinoma cell growth by inducing cell cycle arrest and autophagic cell death. Med Sci Monit. 2015;21:3371-3379.
Zhu G, Gilchrist R, Borley N, Chng HW, Morgan M, Marshall JF, Camplejohn RS, Muir GH, Hart IR. Reduction of TSG101 protein has a negative impact on tumor cell growth. Int J Cancer. 2004;109:541-547.
Zhang Y, Song M, Cui ZS, Li CY, Xue XX, Yu M, Lu Y, Zhang SY, Wang EH, Wen YY. Down-regulation of TSG101 by small interfering RNA inhibits the proliferation of breast cancer cells through the MAPK/ERK signal pathway. Histol Histopathol. 2011;26:87-94.
